Synthesis and Anti-Diabetic Activity of an 8-Purine Derivative as a Novel DPP-4 Inhibitor in Obese Diabetic Zücker Rats

References

• International Diabetes Federation. IDF Diabetes Atlas (10th e). Available from: http://www.diabetes.atlas.org. Accessed April 14, 2023.
   Google Scholar
• Holst JJ, Deacon CF. Inhibition of the activity of dipeptidyl-peptidase IV as a treatment for type 2 diabetes. Diabetes. 1998;47:1663–1670. doi:10.2337/diabetes.47.11.1663
   PubMed Web of Science ®Google Scholar
• Kreymann B, Williams G, Ghatei MA, Bloom SR. Glucagon-like peptide-1: a physiological incretin in man. Lancet. 1987;2:1300–1304. doi:10.1016/s0140-6736(87)91194-9
   PubMed Web of Science ®Google Scholar
• Baggio LL, Drucker DJ. Biology of incretins: GLP-1 and GIP. Gastroenterology. 2007;132:2131–2157. doi:10.1053/j.gastro.2007.03.054
   PubMed Web of Science ®Google Scholar
• Deacon CF, Hughes TE, Holst JJ. Dipeptidyl peptidase IV inhibition potentiates the insulinotropic effect of glucagon-like peptide 1 in the anesthetized pig. Diabetes. 1998;47:764–769. doi:10.2337/diabetes.47.5.764
   PubMed Web of Science ®Google Scholar
• Ahrén B, Simonsson E, Larsson H, et al. Inhibition of dipeptidyl peptidase IV improves metabolic control over a 4-week study period in type 2 diabetes. Diabetes Care. 2002;25:869–875. doi:10.2337/diacare.25.5.869
   PubMed Web of Science ®Google Scholar
• Scheen AJ. The safety of gliptins: updated data in 2018. Expert Opin Drug Saf. 2018;17:387–405. doi:10.1080/14740338.2018.1444027
   PubMed Web of Science ®Google Scholar
• Deacon CF. Dipeptidyl peptidase 4 inhibitors in the treatment of type 2 diabetes. Nat Rev Endocrinol. 2020;16:642–653. doi:10.1038/s41574-020-0399-8
   PubMed Web of Science ®Google Scholar
• Saini K, Sharma S, Khan Y. DPP4 inhibitors for treating T2DM - hype or hope? An analysis based on the current literature. Front Mol Biosci. 2023;10:1130625. doi:10.3389/fmolb.2023.1130625
   PubMed Web of Science ®Google Scholar
• Yin R, Xu Y, Wang X, et al. Role of dipeptidyl peptidase 4 inhibitors in antidiabetic treatment. Molecules. 2022;27(10):3055. doi:10.3390/molecules27103055
   PubMed Web of Science ®Google Scholar
• Semighini EP, Resende JA, de Andrade P, et al. Using computer-aided drug design and medicinal chemistry strategies in the fight against diabetes. J Biomol Struct Dyn. 2011;28:787–796. doi:10.1080/07391102.2011.10508606
   PubMed Web of Science ®Google Scholar
• Peters JW, Weber S, Kritter S, et al. Aminomethylpyrimidines as novel DPP-IV inhibitors: a 105-fold activity increase by optimization of aromatic substituents. Bioorg Med Chem Lett. 2004;14:1491–1493. doi:10.1016/j.bmcl.2004.01.019
   PubMed Web of Science ®Google Scholar
• Peterson R, Shaw W, Neel M, et al. Zücker diabetic fatty rat as a model for non-insulin-dependent diabetes mellitus. ILARNews. 1990;32:16–27. doi:10.1093/ilar.32.3.16
   Google Scholar
• Kasiske BL, O’Donnell MP, Keane WF. The Zücker rat model of obesity, insulin resistance, hyperlipidemia, and renal injury. Hypertension. 1992;19:110–115. doi:10.1161/01.hyp.19.1_suppl.i110
   PubMed Web of Science ®Google Scholar
• Kojima K, Hama T, Kato T, Nagatsu T. Rapid chromatographic purification of dipeptidyl peptidase IV in human submaxillary gland. J Chromatogr. 1980;189(2):233–240. doi:10.1016/s0021-9673(00)81523-x
   PubMed Web of Science ®Google Scholar
• Shafrir E. Animal models of non-insulin-dependent diabetes. Diabetes Metab Rev. 1992;8:179–208. doi:10.1002/dmr.5610080302
   PubMed Web of Science ®Google Scholar
• Aleixandre De Artinano A, Miguel Castro M. Experimental rat models to study the metabolic syndrome. Br J Nutr. 2009;102:1246–1253. doi:10.1017/S0007114509990729
   PubMed Web of Science ®Google Scholar
• Lin SY, Isome Y, Stewart E, Liu J-F, Yohannes D, Yu L. Microwave-assisted one step high-throughput synthesis of benzimidazoles. Tetrahedron Lett. 2006;47:2883–2886. doi:10.1016/j.tetlet.2006.02.127
   Web of Science ®Google Scholar
• Tao H, Kang Y, Taldone T, Chiosis G. Microwave-assisted one step synthesis of 8-arylmethyl-9H-purin-6-amines. Bioorg Med Chem Lett. 2009;19:415–417. doi:10.1016/j.bmcl.2008.11.057
   PubMed Web of Science ®Google Scholar
• Biamonte MA, Shi J, Hurst D, Hong K, Boehm MF, Kasibhatla SR. Preparation of 8-(arylsulfanyl)adenines with diazonium salts under mild, aerobic conditions. J Org Chem. 2005;70(2):717–720. doi:10.1021/jo048522a
   PubMed Web of Science ®Google Scholar
• Davis H, Jones Briscoe V, Dumbadze S, Davis SN. Using DPP-4 inhibitors to modulate beta cell function in type 1 diabetes and in the treatment of diabetic kidney disease. Expert Opin Investig Drugs. 2019;28(4):377–388. doi:10.1080/13543784.2019.1592156
   PubMed Web of Science ®Google Scholar
• Nair AB, Jacob S. A simple practice guide for dose conversion between animals and human. J Basic Clin Pharm. 2016;7(2):27–31. doi:10.4103/0976-0105.177703
   PubMedGoogle Scholar
• Aldakinah AA, Al-Shorbagy MY, Abdallah DM, El-Abhar HS. Trigonelline and vildagliptin antidiabetic effect: improvement of insulin signalling pathway. J Pharm Pharmacol. 2017;69(7):856–864. doi:10.1111/jphp.12713
   PubMed Web of Science ®Google Scholar
• Han SJ, Choi S-E, Kang Y, et al. Effect of sitagliptin plus metformin on b-cell function, islet integrity and islet gene expression in Zücker diabetic fatty rats. Diabet Res Clin Pract. 2011;92:213–222. doi:10.1016/j.diabres.2011.01.016
   PubMed Web of Science ®Google Scholar
• Wang Y, Landheer S, van Gilst WH, et al. Attenuation of renovascular damage in Zücker diabetic fatty rat by NWT-03, an egg protein hydrolysate with ACE- and DPP4-inhibitory Activity. PLoS One. 2012;7(10):e46781. doi:10.1371/journal.pone.0046781
   PubMed Web of Science ®Google Scholar
• Eom YS, Gwon AR, Kwak KM, et al. Protective effects of vildagliptin against pioglitazone-induced bone loss in type 2 diabetic rats. PLoS One. 2016;20(12):e0168569. doi:10.1371/journal.pone.0168569
   Google Scholar
• Refaat R, Sakr A, Salama M, El Sarha A. Combination of vildagliptin and pioglitazone in experimental type 2 diabetes in male rats. Drug Dev Res. 2016;77(6):300–309. doi:10.1002/ddr.21324
   PubMed Web of Science ®Google Scholar
• Keating GM. Vildagliptin: a review of its use in type 2 diabetes mellitus. Drugs. 2014;74(5):587–610. doi:10.1007/s40265-014-0199-3
   PubMed Web of Science ®Google Scholar
• Gupta A, Jacobson GA, Burgess JR, et al. Citrus bioflavonoids dipeptidyl peptidase-4 inhibition compared with gliptin antidiabetic medications. Biochem Biophys Res Commun. 2018;3(1):21–25. doi:10.1016/j.bbrc.2018.04.156
   Google Scholar